Semaglutide vs Tirzepatide: Which GLP-1 Is Better for Weight Loss?

How They Work

Semaglutide and tirzepatide both belong to the incretin family of medications, but they work through different receptor pathways. Understanding that difference is the key to understanding why their clinical results diverge so significantly.

Semaglutide is a GLP-1 receptor agonist. GLP-1 (glucagon-like peptide-1) is a hormone your gut releases after you eat. It does three things that matter for weight loss: it signals your brain to reduce appetite, it slows gastric emptying so food stays in your stomach longer and you feel full, and it stimulates insulin release to help regulate blood sugar. Your body produces GLP-1 naturally, but the natural version breaks down within minutes. Semaglutide is an engineered analog that resists degradation. A single weekly injection maintains active GLP-1 receptor stimulation for a full seven days.

The way semaglutide suppresses appetite is worth understanding. It crosses the blood-brain barrier and acts on GLP-1 receptors in the hypothalamus, the region that regulates hunger and satiety. This is not simply "feeling less hungry." Patients consistently report that the constant mental noise around food -- the cravings, the preoccupation, the effort of willpower -- quiets down. The medication changes the signal, not just the behavior.

Tirzepatide takes a fundamentally different approach. It is a dual GLP-1/GIP receptor agonist, meaning it activates two incretin receptors instead of one. GIP (glucose-dependent insulinotropic polypeptide) is the other major gut hormone involved in metabolic regulation. While GLP-1 has received most of the public attention, GIP is actually the dominant incretin in healthy humans. Your body releases more GIP than GLP-1 after a meal. GIP receptors exist throughout the body -- in fat tissue, the pancreas, the brain, and bone. By engaging both GLP-1 and GIP pathways simultaneously, tirzepatide creates a broader and more potent metabolic effect than GLP-1 stimulation alone.

The GIP component is what separates tirzepatide from every other GLP-1 medication on the market. GIP receptor activation appears to enhance insulin sensitivity independently of GLP-1, improve fat oxidation (the body's ability to burn stored fat for energy), and may contribute to better lean mass preservation during weight loss. There is also emerging evidence that GIP receptor signaling in the brain amplifies the appetite-suppressing effects of GLP-1, effectively making the dual agonist more powerful than either pathway alone. This additive effect may explain why tirzepatide produces meaningfully greater weight loss without a proportional increase in side effects.

Both medications are administered as once-weekly subcutaneous injections using prefilled pen devices. Both require gradual dose titration over several months to manage gastrointestinal side effects. Semaglutide titrates from 0.25 mg up to 2.4 mg (for obesity) across roughly 16-20 weeks. Tirzepatide titrates from 2.5 mg up to 15 mg across a similar timeframe. But despite these structural similarities, their mechanisms produce meaningfully different outcomes in clinical trials.

What the Research Shows

The clinical evidence for both medications is extensive. Multiple large randomized controlled trials involving tens of thousands of participants have been published in top-tier medical journals. The data tells a clear story: both work well, but tirzepatide produces greater average weight loss.

Semaglutide: The STEP Trial Program. The STEP (Semaglutide Treatment Effect in People with Obesity) trials are the cornerstone of semaglutide's obesity evidence base. STEP 1, published in the New England Journal of Medicine in 2021 (PMID: 33567185), enrolled 1,961 adults with obesity or overweight (with at least one weight-related comorbidity) but without diabetes. Participants on semaglutide 2.4 mg lost an average of 14.9% of their body weight at 68 weeks, compared to 2.4% with placebo. One-third of participants lost more than 20% of their body weight. These results were unprecedented for a pharmaceutical weight loss intervention at the time.

The STEP program included multiple follow-up trials. STEP 2 studied adults with type 2 diabetes and showed 9.6% weight loss (lower than STEP 1, which is typical -- patients with diabetes tend to lose less weight on GLP-1 agonists). STEP 3 combined semaglutide with intensive behavioral therapy (meal replacements, exercise coaching, counseling) and achieved 16.0% weight loss, demonstrating that lifestyle intervention adds meaningful benefit on top of the medication. STEP 4 used a randomized withdrawal design, confirming that stopping semaglutide leads to significant weight regain. STEP 5 extended the observation to 104 weeks, showing that weight loss was durable as long as treatment continued, with participants maintaining approximately 15% weight loss at two years.

Tirzepatide: The SURMOUNT Trial Program. The SURMOUNT trials tested tirzepatide specifically for chronic weight management in people without diabetes. SURMOUNT-1, published in the New England Journal of Medicine in 2022 (PMID: 35658024), enrolled 2,539 adults. At 72 weeks, participants lost an average of 15.0% (5 mg dose), 19.5% (10 mg dose), and 20.9% (15 mg dose) of their body weight. Using an estimand that accounted for treatment adherence, the highest dose group achieved 22.5% average weight loss. More than one-third of participants on the 15 mg dose lost more than 25% of their body weight. These results surpassed anything previously seen in obesity pharmacotherapy.

SURMOUNT-2 studied tirzepatide in adults with obesity and type 2 diabetes (PMID: 37840095). Even in this harder-to-treat population, tirzepatide 15 mg produced 14.7% weight loss at 72 weeks. SURMOUNT-3 and SURMOUNT-4 examined intensive lifestyle therapy combinations and treatment withdrawal, paralleling the STEP program's design. The consistent finding across all SURMOUNT trials: tirzepatide at maximum doses produces 5-8 percentage points more weight loss than semaglutide at maximum doses in comparable populations.

Head-to-Head: SURPASS-2. The most direct comparison comes from SURPASS-2, published in 2021 (PMID: 34170647). This trial compared tirzepatide (5 mg, 10 mg, and 15 mg) to semaglutide 1 mg in 1,879 patients with type 2 diabetes. Tirzepatide at all three doses produced superior A1C reductions and greater weight loss than semaglutide 1 mg. At 40 weeks, weight loss was 7.6 kg (semaglutide 1 mg), 9.2 kg (tirzepatide 5 mg), 11.1 kg (tirzepatide 10 mg), and 12.4 kg (tirzepatide 15 mg).

Important caveat: SURPASS-2 used semaglutide at 1 mg, which is the diabetes dose, not 2.4 mg, which is the obesity dose. A true head-to-head comparison at maximum weight-management doses has not been published. Indirect cross-trial comparisons consistently favor tirzepatide, but the field awaits a definitive head-to-head at full obesity doses.

Cardiovascular Outcomes: SELECT. Semaglutide holds a significant advantage in long-term cardiovascular outcomes data. The SELECT trial (PMID: 37952131), published in the New England Journal of Medicine in 2023, was a massive study enrolling 17,604 adults aged 45 and older with overweight or obesity and established cardiovascular disease but without diabetes. Semaglutide reduced major adverse cardiovascular events (a composite of heart attack, stroke, and cardiovascular death) by 20% compared to placebo over a mean follow-up of 39.8 months. This was a landmark finding that changed how the medical community views obesity treatment. It proved that semaglutide does more than reduce body weight -- it directly reduces the risk of heart attacks and strokes.

Tirzepatide does not yet have a completed cardiovascular outcomes trial of this magnitude. The SURPASS-CVOT trial is underway and will provide this data, but results are not expected for several years. For patients with established cardiovascular disease, this data gap is clinically relevant.

What the numbers mean in practice. Across the trial programs, semaglutide at 2.4 mg produces 15-17% average body weight loss. Tirzepatide at 15 mg produces 20-26%. For a 250-pound person, that translates to roughly 40 pounds lost on semaglutide versus 55 pounds on tirzepatide. These are population averages. Individual responses range widely. Some people lose 30% or more on tirzepatide. Others lose 8%. Genetics, baseline metabolic health, diet quality, physical activity, starting weight, and medication adherence all influence outcomes. Neither medication is a guarantee of any specific result.

Side Effects and Tolerability

The side effect profiles of semaglutide and tirzepatide overlap heavily. Gastrointestinal symptoms dominate for both, especially during the titration phase when doses are increasing. Most side effects are transient and manageable. Serious adverse events are uncommon.

Nausea is the headline side effect for both medications. In STEP 1, 44.2% of semaglutide participants reported nausea at some point during the trial, though for the majority it was mild to moderate and resolved with continued use. In SURMOUNT-1, nausea rates were 24.6% (5 mg), 33.3% (10 mg), and 31.0% (15 mg) for tirzepatide. Vomiting followed a similar pattern: 24.8% for semaglutide 2.4 mg versus 8.3-12.2% across tirzepatide doses. Diarrhea occurred in roughly 30% of semaglutide users and 17-21% of tirzepatide users. Constipation affected 24% on semaglutide and 11-17% on tirzepatide.

These cross-trial comparisons have inherent limitations (different populations, different time points, different measurement protocols), but the consistent pattern suggests tirzepatide may cause fewer GI side effects at comparable or even greater weight loss efficacy. The GIP receptor component is the likely explanation. GIP signaling appears to partially buffer the gastrointestinal disturbance that pure GLP-1 receptor agonism causes, essentially smoothing out the appetite suppression without as much nausea.

Titration pace matters more than most people realize. The majority of GI side effects occur during dose escalation, not at stable maintenance doses. Both medications use slow titration schedules -- typically four-week steps -- specifically to allow the body to adapt. Patients who rush titration, skip dose steps, or receive starting doses that are too high tend to experience significantly worse nausea and vomiting. Patients who follow the prescribed titration schedule typically see GI symptoms peak in weeks two through three of each new dose level and then gradually fade. This is why most clinical guidelines emphasize patience during the titration phase.

Serious adverse events are rare for both medications. In the major trials, rates of acute pancreatitis were low (less than 0.3%) and not statistically different between drug and placebo groups. Gallbladder events (gallstones, cholecystitis) occurred at slightly higher rates in treatment groups, consistent with rapid weight loss from any cause. Both medications carry an FDA boxed warning about the risk of medullary thyroid carcinoma based on findings in rodent studies, though this has not been observed in human clinical trials or post-market surveillance. The overall dropout rate due to adverse events was 4.5% for semaglutide 2.4 mg in STEP 1 and ranged from 4.3% to 7.1% across tirzepatide doses in SURMOUNT-1. These are low discontinuation rates for a chronic medication.

Muscle loss is a legitimate concern with both medications. This is the trade-off that does not get enough attention. Rapid weight loss from any intervention -- surgical, pharmacological, or dietary -- results in some loss of lean body mass alongside fat mass. In STEP 1, body composition data showed that approximately 39% of the total weight lost with semaglutide was lean mass, including muscle. Tirzepatide data from SURMOUNT-1 and related substudies suggested a somewhat more favorable ratio, with a higher proportion of fat mass lost relative to lean mass. Some researchers attribute this to GIP receptor activation in muscle and adipose tissue, though the evidence is still emerging.

Neither medication eliminates muscle loss. This is why every major clinical guideline recommends resistance training (at least two sessions per week) and adequate protein intake (1.0-1.2 grams per kilogram of body weight per day, and some experts recommend even higher) alongside either treatment. Patients who combine GLP-1 therapy with structured strength training consistently show better body composition outcomes than those who rely on the medication alone.

Injection site reactions are mild and uncommon with both medications. Localized pain, redness, or itching at the injection site occurs in fewer than 5% of users. These reactions are transient and rarely lead to treatment discontinuation.

Cost, Access, and Practical Considerations

Efficacy and tolerability data only matter if you can actually get the medication into your hands. For many people, cost, insurance coverage, and supply reliability are the factors that ultimately determine which medication they use -- or whether they can use either one at all.

Brand-name pricing remains a barrier for most patients. Wegovy (semaglutide 2.4 mg for chronic weight management) carries a list price of roughly $1,350 per month. Zepbound (tirzepatide for chronic weight management) lists at approximately $1,060 per month. The diabetes-indicated versions -- Ozempic (semaglutide) and Mounjaro (tirzepatide) -- fall in a similar range of $900-1,100 per month. Without insurance coverage or manufacturer savings programs, these prices put both medications out of reach for the majority of patients. Novo Nordisk and Eli Lilly both offer savings cards and patient assistance programs, but eligibility criteria vary and these programs typically exclude patients on government insurance (Medicare, Medicaid).

Insurance coverage currently favors semaglutide, but the gap is narrowing. Semaglutide reached the market first. Wegovy received FDA approval for chronic weight management in June 2021. Zepbound followed in November 2023. That two-year head start gave semaglutide more time to negotiate formulary placement, establish prior authorization pathways, and build insurance coverage networks. As of early 2026, more commercial insurance plans list Wegovy on their formularies than Zepbound. However, tirzepatide coverage is expanding rapidly as payers respond to the clinical data. Medicare Part D does not currently cover any anti-obesity medications, a policy that affects millions of eligible patients. Several legislative efforts are underway to change this, but as of this writing, Medicare patients must pay out of pocket.

Compounding pharmacies changed the access equation. When both semaglutide and tirzepatide were placed on the FDA Drug Shortage List, compounding pharmacies gained the legal authority to produce copies of these medications at significantly lower prices. Compounded semaglutide became widely available through telehealth platforms at prices ranging from $150 to $400 per month, depending on dose and pharmacy. Compounded tirzepatide followed, though availability has been more variable and pricing slightly higher in many cases.

The compounding landscape is shifting. The FDA has moved to resolve shortage designations as branded supply has stabilized, which could restrict or eliminate compounded access. This has created uncertainty for patients who rely on compounded versions. Litigation between compounding pharmacies and manufacturers is ongoing. Patients using compounded versions should stay informed about regulatory changes and have a contingency plan.

Supply shortages have affected both medications at various points. Semaglutide experienced severe and prolonged supply constraints from 2022 through 2024. Specific dose strengths (particularly the 1.0 mg and 1.7 mg titration steps for Wegovy) were frequently unavailable, forcing patients to delay titration or switch medications. Tirzepatide experienced similar intermittent shortages, particularly at the 10 mg and 15 mg dose strengths. As of early 2026, supply for both has improved substantially, but intermittent spot shortages remain possible. Patients who are mid-titration are most vulnerable to supply disruptions, since skipping a dose step can reset tolerance and worsen side effects when treatment resumes.

Switching between the two medications is straightforward. Patients who respond poorly to one medication, experience intolerable side effects, or face access issues can switch to the other under medical supervision. There is no required washout period between them. Most clinicians start the new medication at its lowest dose and follow the standard titration schedule regardless of what dose the patient was on previously. This conservative approach minimizes side effects during the transition. Some experienced prescribers will use clinical judgment to start at a slightly higher dose if the patient previously tolerated a comparable level of GLP-1 agonism, but this is an individualized decision.

The Bottom Line

Neither semaglutide nor tirzepatide is universally "better." The right choice depends on your specific health goals, your insurance and financial situation, your tolerance for side effects, and what your physician recommends based on your individual medical history.

If maximum weight loss is the primary goal and access is not a barrier, tirzepatide has the stronger data. The dual GLP-1/GIP mechanism produces 5-8 percentage points more weight loss on average, with potentially better tolerability and a more favorable body composition profile. If you value the longest clinical track record, the most extensive long-term safety data, and proven cardiovascular risk reduction backed by the SELECT trial, semaglutide has a meaningful and clinically significant edge. For patients with established heart disease, the cardiovascular outcomes data may be the deciding factor.

For many people, the deciding factor will not be clinical trial data at all. It will be which medication their insurance covers, which one their pharmacy has in stock, and which one their body tolerates without side effects that disrupt daily life. Both are effective, FDA-approved tools for chronic weight management. Both require ongoing treatment to maintain results -- stopping either medication leads to significant weight regain in the majority of patients. And both work best when combined with dietary changes, regular physical activity (including resistance training), adequate protein intake, and consistent medical supervision.